Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

O'Brien DA, Poppas P, Kaye SM, Mahase SS, An A, Christos PJ, et al. Timing of Adjuvant Fractionated Stereotactic Radiosurgery Affects Local Control of Resected Brain Metastases. Pract Radiat Oncol. 2021;11(3):e267-e275.

Zoughbi WA, Kim D, Alperstein SA, Ohara K, Manohar J, Greco N, et al. Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience. Cancer Cytopathol. 2021.

Ke Q, Dinalankara W, Younes L, Geman D, Marchionni L. Efficient representations of tumor diversity with paired DNA-RNA aberrations. PLoS Comput Biol. 2021;17(6):e1008944.

Narayanan D, Pozdnyakova O, Hasserjian RP, Patel SS, Weinberg OK. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. Blood Adv. 2021;5(11):2539-2549.

Huang Z, Ning B, Yang HS, Youngquist BM, Niu A, Lyon CJ, et al. Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection. J Clin Invest. 2021;131(7).

Egan CE, Stefanova D, Ahmed A, Raja VJ, Thiesmeyer JW, Chen KJ, et al. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer. Thyroid. 2021.

Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, et al. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. J Rheumatol. 2021;48(4):541-547.

Hansen G, Marino J, Wang Z-, Beavis KG, Rodrigo J, Labog K, et al. Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study. J Clin Microbiol. 2021;59(2).

Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, et al. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 2021;11(8):2014-2031.

Sun M, Schaap A, Robinson BD, Nanus DM, Tagawa ST. A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. Am J Clin Exp Urol. 2021;9(5):390-396.